{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:50:16Z","timestamp":1764856216539,"version":"3.46.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Can J Public Health"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.17269\/s41997-024-00968-5","type":"journal-article","created":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T12:49:35Z","timestamp":1732625375000},"page":"806-813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term serological response and boostability of intradermal rabies immunization: A retrospective chart review"],"prefix":"10.17269","volume":"116","author":[{"given":"Eileen J.","family":"Burnett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel J.","family":"Mcpherson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua P.","family":"Aquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3089-4335","authenticated-orcid":false,"given":"Pierre J.","family":"Plourde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,26]]},"reference":[{"key":"968_CR1","doi-asserted-by":"publisher","unstructured":"Bui, Y., Sow, M., Cambron-Goulet, E., Levac, E., & Milord, F. (2015). Immunogenicity and feasibility of intradermal vaccination against rabies in Quebec. Canada Communicable Disease Report, 41(3), 55\u201362. https:\/\/doi.org\/10.14745\/ccdr.v41i03a03","DOI":"10.14745\/ccdr.v41i03a03"},{"key":"968_CR2","unstructured":"Canadian Communicable Disease Report. (2002). Committee to Advise on Tropical Medicine and Travel (CATMAT): Statement on travellers and rabies vaccine. CCDR, 28(4). Health Canada."},{"issue":"1","key":"968_CR3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S0022-1759(97)00212-3","volume":"212","author":"F Cliquet","year":"1998","unstructured":"Cliquet, F., Aubert, M., & Sagn\u00e9, L. (1998). Development of a fluorescent antibody virus neutralisation test (FAVN test) for the quantitation of rabies-neutralising antibody. Journal of Immunological Methods, 212(1), 79\u201387. https:\/\/doi.org\/10.1016\/S0022-1759(97)00212-3","journal-title":"Journal of Immunological Methods"},{"issue":"9","key":"968_CR4","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1093\/infdis\/jiz645","volume":"221","author":"TP Endy","year":"2020","unstructured":"Endy, T. P., Keiser, P. B., Wang, D., Jarman, R. G., Cibula, D., Fang, H., Ware, L., Abbott, M., Thomas, S. J., & Polhemus, M. E. (2020). Serologic response of 2 versus 3 doses and intradermal versus intramuscular administration of a licensed rabies vaccine for preexposure prophylaxis. The Journal of Infectious Diseases, 221(9), 1494\u20131498. https:\/\/doi.org\/10.1093\/infdis\/jiz645","journal-title":"The Journal of Infectious Diseases"},{"issue":"13","key":"968_CR5","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.vaccine.2022.02.041","volume":"40","author":"A Filia","year":"2022","unstructured":"Filia, A., Rota, M. C., Grossi, A., Martinelli, D., Prato, R., & Rezza, G. (2022). Are vaccine shortages a relevant public health issue in Europe? Results from a survey conducted in the framework of the EU Joint Action on Vaccination. Vaccine, 40(13), 1987\u20131995. https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.041","journal-title":"Vaccine"},{"key":"968_CR6","unstructured":"GlaxoSmithKline. (2019). RABAVERT rabies vaccine prodcut monograph. https:\/\/pdf.hres.ca\/dpd_pm\/00049797.PDF"},{"issue":"2","key":"968_CR7","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.9778\/cmajo.20170147","volume":"6","author":"LY Kong","year":"2018","unstructured":"Kong, L. Y., Vincelette, J., Laplante, G., Duchesne, J.-A., Libman, M., & Barkati, S. (2018). Intradermal pre-exposure rabies vaccination in a Canadian travel clinic: 6-year retrospective observational study. CMAJ Open, 6(2), E168\u2013E175. https:\/\/doi.org\/10.9778\/cmajo.20170147","journal-title":"CMAJ Open"},{"key":"968_CR8","doi-asserted-by":"publisher","unstructured":"Mills, D. J., Lau, C. L., Mills, C., & Furuya-Kanamori, L. (2022). Long-term persistence of antibodies and boostability after rabies intradermal pre-exposure prophylaxis. Journal of Travel Medicine, 29(2), taab188. https:\/\/doi.org\/10.1093\/jtm\/taab188","DOI":"10.1093\/jtm\/taab188"},{"issue":"1","key":"968_CR9","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/tropicalmed5010040","volume":"5","author":"T Moulenat","year":"2020","unstructured":"Moulenat, T., Petit, C., Bosch Castells, V., & Houillon, G. (2020). Purified Vero cell rabies vaccine (PVRV, Verorab\u00ae): A systematic review of intradermal use between 1985 and 2019. Tropical Medicine and Infectious Disease, 5(1), 40. https:\/\/doi.org\/10.3390\/tropicalmed5010040","journal-title":"Tropical Medicine and Infectious Disease"},{"key":"968_CR10","doi-asserted-by":"publisher","unstructured":"Mpolya, E. A., Lembo, T., Lushasi, K., Mancy, R., Mbunda, E. M., Makungu, S., Maziku, M., Sikana, L., Jaswant, G., Townsend, S., Meslin, F.-X., Abela-Ridder, B., Ngeleja, C., Changalucha, J., Mtema, Z., Sambo, M., Mchau, G., Rysava, K., Nanai, A.,\u00a0Kazwala, R., Cleaveland, S.,\u00a0Hampson, K. (2017). Toward elimination of dog-mediated human rabies: Experiences from implementing a large-scale demonstration project in Southern Tanzania. Frontiers in Veterinary Science, 4. https:\/\/doi.org\/10.3389\/fvets.2017.00021","DOI":"10.3389\/fvets.2017.00021"},{"key":"968_CR11","unstructured":"Public Health Agency of Canada. (2015). Rabies vaccine: Canadian immunization guide. Canadian Immunization Guide: Part 4 - Active Vaccines. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-18-rabies-vaccine.html"},{"key":"968_CR12","doi-asserted-by":"publisher","unstructured":"Rao, A. K., Briggs, D., Moore, S. M., Whitehill, F., Campos-Outcalt, D., Morgan, R. L., Wallace, R. M., Romero, J. R., Bahta, L., Frey, S. E., & Blanton, J. D. (2022). Use of a modified preexposure prophylaxis vaccination schedule to prevent human rabies: Recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2022. MMWR. Morbidity and Mortality Weekly Report, 71(18), 619\u2013627. https:\/\/doi.org\/10.15585\/mmwr.mm7118a2","DOI":"10.15585\/mmwr.mm7118a2"},{"key":"968_CR13","unstructured":"Sanofi Pasteur Inc. (2019). Rabies vaccine Imovax Rabies. https:\/\/www.fda.gov\/media\/75709\/download"},{"issue":"4","key":"968_CR14","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/cid\/ciy513","volume":"68","author":"P Soentjens","year":"2019","unstructured":"Soentjens, P., Andries, P., Aerssens, A., Tsoumanis, A., Ravinetto, R., Heuninckx, W., Van Loen, H., Brochier, B., Van Gucht, S., Van Damme, P., Van Herrewege, Y., & Bottieau, E. (2019). Preexposure intradermal rabies vaccination: A noninferiority trial in healthy adults on shortening the vaccination schedule from 28 to 7 days. Clinical Infectious Diseases, 68(4), 607\u2013614. https:\/\/doi.org\/10.1093\/cid\/ciy513","journal-title":"Clinical Infectious Diseases"},{"key":"968_CR15","doi-asserted-by":"publisher","unstructured":"Soentjens, P., & Croughs, M. (2020). Stock shortages of the rabies vaccine in Belgium: Implications for pretravel advice. Journal of Travel Medicine, 27(7), taz076. https:\/\/doi.org\/10.1093\/jtm\/taz076","DOI":"10.1093\/jtm\/taz076"},{"issue":"7","key":"968_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.4161\/hv.7.7.15410","volume":"7","author":"R Verma","year":"2011","unstructured":"Verma, R., Khanna, P., Prinja, S., & Rajput, M. (2011). Intra-dermal administration of rabies vaccines in developing countries: At an affordable cost. Human Vaccines, 7(7), 792\u2013794. https:\/\/doi.org\/10.4161\/hv.7.7.15410","journal-title":"Human Vaccines"},{"key":"968_CR17","unstructured":"World Health Organization. (2018). WHO expert consultation on rabies: Third report. World Health Organization. https:\/\/apps.who.int\/iris\/handle\/10665\/272364"},{"issue":"7","key":"968_CR18","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.vaccine.2021.01.023","volume":"39","author":"C Xu","year":"2021","unstructured":"Xu, C., Lau, C. L., Clark, J., Rafferty, A. C., Mills, D. J., Ramsey, L., Gilbert, B., Doi, S. A. R., & Furuya-Kanamori, L. (2021). Immunogenicity after pre- and post-exposure rabies vaccination: A systematic review and dose-response meta-analysis. Vaccine, 39(7), 1044\u20131050. https:\/\/doi.org\/10.1016\/j.vaccine.2021.01.023","journal-title":"Vaccine"},{"key":"968_CR19","doi-asserted-by":"publisher","unstructured":"Ziesenitz, V. C., Mazer-Amirshahi, M., Zocchi, M. S., Fox, E. R., & May, L. S. (2017). U.S. vaccine and immune globulin product shortages, 2001\u201315. American Journal of Health-System Pharmacy, 74(22), 1879\u20131886. https:\/\/doi.org\/10.2146\/ajhp170066","DOI":"10.2146\/ajhp170066"}],"container-title":["Canadian Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-024-00968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.17269\/s41997-024-00968-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.17269\/s41997-024-00968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T13:46:12Z","timestamp":1764855972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.17269\/s41997-024-00968-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,26]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["968"],"URL":"https:\/\/doi.org\/10.17269\/s41997-024-00968-5","relation":{},"ISSN":["0008-4263","1920-7476"],"issn-type":[{"type":"print","value":"0008-4263"},{"type":"electronic","value":"1920-7476"}],"subject":[],"published":{"date-parts":[[2024,11,26]]},"assertion":[{"value":"21 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of Manitoba Health Research Ethics Board (H2022:272), Shared Health Research Impact (SH2022:188), and the Manitoba Provincial Health Research Privacy Committee (No. P2022-108) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}